TerminatedPhase 2NCT06005428
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Studying Catecholaminergic polymorphic ventricular tachycardia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cardurion Pharmaceuticals, Inc.
- Principal Investigator
- Jason Homsy, M.D., Ph.D.Executive Medical Director
- Intervention
- CRD-4730(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2023 – 2025
Study locations (11)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Cleveland Clinic Children's Hospital, Cleveland, Ohio, United States
- Baylor College of Medicine, Houston, Texas, United States
- Stollery Children's Hospital University of Alberta, Edmonton, Alberta, Canada
- University of British Columbia (UBC) Hospital, Vancouver, British Columbia, Canada
- British Columbia Children's Hospital, Vancouver, British Columbia, Canada
- University of Western Ontario, London, Ontario, Canada
- Hôptal Nord Laennec, Nantes, Loire-Atlantique, France
- Hôpital Louis Pradel, Bron, France
- Groupe Hospitalier Bichat Claude Bernard, Paris, France
- IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit, Pavia, Lombardy, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06005428 on ClinicalTrials.govOther trials for Catecholaminergic polymorphic ventricular tachycardia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07148089A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Solid Biosciences Inc.
- RECRUITINGPHASE2NCT07263139Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Agiana Pharmaceuticals
- RECRUITINGPHASE2NCT06658899A Phase 2 Study of CRD-4730 in CPVTCardurion Pharmaceuticals, Inc.
- RECRUITINGNCT06661278Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited ArrhythmiasRoyal Brompton & Harefield NHS Foundation Trust
See all trials for Catecholaminergic polymorphic ventricular tachycardia →